These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 14031846)
21. Pharma's year of trouble and strife. Frantz S Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339 [No Abstract] [Full Text] [Related]
22. Into the unknown: AIDS patients test drugs. Navarro M N Y Times Web; 1992 Feb; ():1, 29. PubMed ID: 11646911 [No Abstract] [Full Text] [Related]
23. Synthetic approaches to the 2003 new drugs. Liu KK; Li J; Sakya S Mini Rev Med Chem; 2004 Dec; 4(10):1105-25. PubMed ID: 15579116 [TBL] [Abstract][Full Text] [Related]
24. From the Food and Drug Administration. Nightingale SL JAMA; 1991 Apr; 265(14):1802. PubMed ID: 1848642 [No Abstract] [Full Text] [Related]
25. Recent disclosures of clinical drug candidates. Armer R; Warne P; Witherington J Drug News Perspect; 2006; 19(1):65-72. PubMed ID: 16550257 [TBL] [Abstract][Full Text] [Related]
27. Individual patient treatment use of unapproved drugs: a new option for the seriously ill. Simon LS; Green A J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):19-22. PubMed ID: 20345195 [TBL] [Abstract][Full Text] [Related]
28. A new miracle drug in the Caucasus? Lampert FH Med Pediatr Oncol; 2003 Nov; 41(5):452-3. PubMed ID: 14515386 [No Abstract] [Full Text] [Related]
29. [Patents and availability of essential drugs]. Carné X Med Clin (Barc); 2007 Nov; 129(16):617-8. PubMed ID: 18001674 [No Abstract] [Full Text] [Related]
30. [The Contribution of GMP-grade Hospital Preparation to Translational Research]. Yonezawa A; Kajiwara M; Minami I; Omura T; Nakagawa S; Matsubara K Yakugaku Zasshi; 2015; 135(8):943-7. PubMed ID: 26234351 [TBL] [Abstract][Full Text] [Related]
31. "Pharmacogenomics: achievements, challenges and prospects, for patients, pharmaceutical industries and healthcare systems". Sanoudou D Curr Pharm Des; 2010; 16(20):2182-3. PubMed ID: 20459384 [No Abstract] [Full Text] [Related]
32. [New drugs in Spain -- when are they to be considered cost-effective alternatives and profitable investments for the National Health System? ]. Soto Alvarez J Farm Hosp; 2004; 28(4):299-304. PubMed ID: 15369442 [No Abstract] [Full Text] [Related]
33. An audience with... Victoria G. Hale. Hale VG Nat Rev Drug Discov; 2005 Nov; 4(11):878. PubMed ID: 16299916 [No Abstract] [Full Text] [Related]
34. Drug assistance from drug makers. Hanson K State Legis; 2003 Jun; 29(6):22-4. PubMed ID: 12785350 [TBL] [Abstract][Full Text] [Related]
35. The FDA's response to AIDS: paradigm shift in new drug policy? Podraza R Food Drug Law J; 1993; 48(3):351-75. PubMed ID: 11653267 [No Abstract] [Full Text] [Related]